Bernstein Maintains Outperform on Insulet, Lowers Price Target to $175

Benzinga Newsdesk www.benzinga.com Negative 95.2%

Neg 95.2% Neu 0% Pos 0%

Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $175.